What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call
SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript
SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript
SAB Biotherapeutics Inc (SABS) (Q3 2026) Earnings Call Highlights: FDA Fast-Track Win, Full ...
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
SAB Biotherapeutics Q3 2026 Earnings Call Transcript
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.